182 related articles for article (PubMed ID: 31571332)
1. Efficacy of the NCCV Cocktail-1 vaccine for refractory pediatric solid tumors: A phase I clinical trial.
Akazawa Y; Hosono A; Yoshikawa T; Kaneda H; Nitani C; Hara J; Kinoshita Y; Kohashi K; Manabe A; Fukutani M; Wakabayashi M; Sato A; Shoda K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T
Cancer Sci; 2019 Dec; 110(12):3650-3662. PubMed ID: 31571332
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors.
Tsuchiya N; Hosono A; Yoshikawa T; Shoda K; Nosaka K; Shimomura M; Hara J; Nitani C; Manabe A; Yoshihara H; Hosoya Y; Kaneda H; Kinoshita Y; Kohashi K; Yoshimura K; Fujinami N; Saito K; Mizuno S; Nakatsura T
Oncoimmunology; 2017; 7(1):e1377872. PubMed ID: 29296538
[TBL] [Abstract][Full Text] [Related]
3. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer.
Asahara S; Takeda K; Yamao K; Maguchi H; Yamaue H
J Transl Med; 2013 Nov; 11():291. PubMed ID: 24237633
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.
Sawada Y; Yoshikawa T; Nobuoka D; Shirakawa H; Kuronuma T; Motomura Y; Mizuno S; Ishii H; Nakachi K; Konishi M; Nakagohri T; Takahashi S; Gotohda N; Takayama T; Yamao K; Uesaka K; Furuse J; Kinoshita T; Nakatsura T
Clin Cancer Res; 2012 Jul; 18(13):3686-96. PubMed ID: 22577059
[TBL] [Abstract][Full Text] [Related]
6. Phase I Study of Multiple Epitope Peptide Vaccination in Patients With Recurrent or Persistent Cervical Cancer.
Hasegawa K; Ikeda Y; Kunugi Y; Kurosaki A; Imai Y; Kohyama S; Nagao S; Kozawa E; Yoshida K; Tsunoda T; Nakamura Y; Fujiwara K
J Immunother; 2018 May; 41(4):201-207. PubMed ID: 29432282
[TBL] [Abstract][Full Text] [Related]
7. Multiple therapeutic peptide vaccines for patients with advanced gastric cancer.
Fujiwara Y; Okada K; Omori T; Sugimura K; Miyata H; Ohue M; Kobayashi S; Takahashi H; Nakano H; Mochizuki C; Shimizu K; Yano M; Nakamura Y; Mori M; Doki Y
Int J Oncol; 2017 May; 50(5):1655-1662. PubMed ID: 28393243
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer.
Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
J Transl Med; 2014 Mar; 12():61. PubMed ID: 24606884
[TBL] [Abstract][Full Text] [Related]
9. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.
Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678
[TBL] [Abstract][Full Text] [Related]
10. Clinical Trial of a Cancer Vaccine Targeting VEGF and KIF20A in Advanced Biliary Tract Cancer.
Murahashi M; Tsuruta T; Yamada K; Hijikata Y; Ogata H; Kishimoto J; Yoshimura S; Hikichi T; Nakanishi Y; Tani K
Anticancer Res; 2021 Mar; 41(3):1485-1496. PubMed ID: 33788741
[TBL] [Abstract][Full Text] [Related]
11. Induction of cytolytic T lymphocytes against pediatric solid tumors in vitro using autologous dendritic cells pulsed with necrotic primary tumor.
Shilyansky J; Jacobs P; Doffek K; Sugg SL
J Pediatr Surg; 2007 Jan; 42(1):54-61; discussion 61. PubMed ID: 17208541
[TBL] [Abstract][Full Text] [Related]
12. First-in-human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors.
Kondo S; Shimizu T; Koyama T; Sato J; Iwasa S; Yonemori K; Fujiwara Y; Shimomura A; Kitano S; Tamura K; Yamamoto N
Cancer Sci; 2021 Apr; 112(4):1514-1523. PubMed ID: 33615628
[TBL] [Abstract][Full Text] [Related]
13. Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial.
Shimizu Y; Yoshikawa T; Kojima T; Shoda K; Nosaka K; Mizuno S; Wada S; Fujimoto Y; Sasada T; Kohashi K; Bando H; Endo I; Nakatsura T
Cancer Sci; 2019 Oct; 110(10):3049-3060. PubMed ID: 31390678
[TBL] [Abstract][Full Text] [Related]
14. First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.
Ishihara M; Tono Y; Miyahara Y; Muraoka D; Harada N; Kageyama S; Sasaki T; Hori Y; Soga N; Uchida K; Shiraishi T; Sato E; Kanda H; Mizuno T; Webster GA; Ikeda H; Katayama N; Sugimura Y; Shiku H
Cancer Immunol Immunother; 2020 Apr; 69(4):663-675. PubMed ID: 31980914
[TBL] [Abstract][Full Text] [Related]
15. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.
Tsuboi A; Hashimoto N; Fujiki F; Morimoto S; Kagawa N; Nakajima H; Hosen N; Nishida S; Nakata J; Morita S; Sakamoto J; Oji Y; Oka Y; Sugiyama H
Cancer Immunol Immunother; 2019 Feb; 68(2):331-340. PubMed ID: 30430205
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin.
Matsumoto K; Noguchi M; Satoh T; Tabata K; Fujita T; Iwamura M; Yamada A; Komatsu N; Baba S; Itoh K
BJU Int; 2011 Sep; 108(6):831-8. PubMed ID: 21166757
[TBL] [Abstract][Full Text] [Related]
17. Significant clinical response of advanced colon cancer to peptide vaccine therapy: a case report.
Yasuda S; Tsuchiya I; Okada K; Tanaka A; Suzuki T; Sadahiro S; Takeda K; Yamamoto S; Nakui M
Tokai J Exp Clin Med; 2012 Jul; 37(2):57-61. PubMed ID: 22763829
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
[TBL] [Abstract][Full Text] [Related]
19. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.
Oji Y; Hashimoto N; Tsuboi A; Murakami Y; Iwai M; Kagawa N; Chiba Y; Izumoto S; Elisseeva O; Ichinohasama R; Sakamoto J; Morita S; Nakajima H; Takashima S; Nakae Y; Nakata J; Kawakami M; Nishida S; Hosen N; Fujiki F; Morimoto S; Adachi M; Iwamoto M; Oka Y; Yoshimine T; Sugiyama H
Int J Cancer; 2016 Sep; 139(6):1391-401. PubMed ID: 27170523
[TBL] [Abstract][Full Text] [Related]
20. WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.
Oka Y; Tsuboi A; Fujiki F; Li Z; Nakajima H; Hosen N; Shirakata T; Nishida S; Oji Y; Kawase I; Sugiyama H
Anticancer Agents Med Chem; 2009 Sep; 9(7):787-97. PubMed ID: 19538172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]